



Article

Achilles Tendon Rupture and Dysmetabolic Diseases: A Multicentric, Epidemiologic Study

Francesco Oliva ¹, Emanuela Marsilio ^{1,*} , Giovanni Asparago ¹ , Alessio Gai Via ², Carlo Biz ³ , Johnny Padulo ⁴ , Marco Spoliti ⁵, Calogero Foti ⁶ , Gabriella Oliva ⁷, Stefania Mannarini ^{8,9}, Alessandro Alberto Rossi ^{8,9} , Pietro Ruggieri ³ and Nicola Maffulli ^{1,10,11}

- ¹ Department of Medicine, Surgery and Dentistry, University of Salerno, Via S. Allende, 84081 Baronissi, Italy; olivafrancesco@hotmail.com (F.O.); giovanni.asparago@gmail.com (G.A.); n.maffulli@qmul.ac.uk (N.M.)
 - ² Department of Orthopaedic Surgery and Traumatology, San Camillo-Forlanini Hospital, 00152 Rome, Italy; alessiogiaivia@hotmail.it
 - ³ Orthopaedics and Orthopaedic Oncology, Department of Surgery, Oncology and Gastroenterology DiSCOG, University of Padua, 35128 Padova, Italy; carlo.biz@unipd.it (C.B.); pietro.ruggieri@unipd.it (P.R.)
 - ⁴ Department of Biomedical Sciences for Health, Università degli Studi di Milano, 20133 Milan, Italy; johnny.padulo@unimi.it
 - ⁵ Orthopaedics and Traumatology Unit, Department of Emergency and Acceptance, Azienda Ospedaliera San Camillo-Forlanini, 00152 Rome, Italy; marcodoc@me.com
 - ⁶ Physical and Rehabilitation Medicine, Clinical Sciences and Translational Medicine Department, Tor Vergata University, 00133 Rome, Italy; foti@med.uniroma2.it
 - ⁷ Department of Internal Medicine, Ospedale del Mare, ASL1, 80147 Napoli, Italy; gably@libero.it
 - ⁸ Department of Philosophy, Sociology, Education, and Applied Psychology, Section of Applied Psychology, University of Padova, 35128 Padova, Italy; stefania.mannarini@unipd.it (S.M.); a.rossi@unipd.it (A.A.R.)
 - ⁹ Interdepartmental Center for Family Research, University of Padova, 35128 Padova, Italy
 - ¹⁰ School of Pharmacy and Bioengineering, Keele University Faculty of Medicine, Thornburrow Drive, Stoke on Trent ST4 7QB, UK
 - ¹¹ Centre for Sports and Exercise Medicine, Barts and the London School of Medicine and Dentistry, Mile End Hospital, Queen Mary University of London, 275 Bancroft Road, London E1 4DG, UK
- * Correspondence: emanuelamarsilio16@gmail.com; Tel.: +39-3465115396



Citation: Oliva, F.; Marsilio, E.; Asparago, G.; Gai Via, A.; Biz, C.; Padulo, J.; Spoliti, M.; Foti, C.; Oliva, G.; Mannarini, S.; et al. Achilles Tendon Rupture and Dysmetabolic Diseases: A Multicentric, Epidemiologic Study. *J. Clin. Med.* **2022**, *11*, 3698. <https://doi.org/10.3390/jcm11133698>

Academic Editor: Heinrich Resch

Received: 16 May 2022

Accepted: 24 June 2022

Published: 27 June 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: **Introduction:** Achilles tendon ruptures are common. Metabolic disorders, such as diabetes mellitus, hypercholesterolemia, thyroid disorders, and obesity, impair tendons health, leading to Achilles tendinopathy and likely predisposing patients to Achilles tendon ruptures. **Materials and methods:** Patients who visited the Orthopedic Outpatient Clinics and the Accident and Emergency Departments of five different hospitals in Italy were recruited. Through telephone interviews, we administered a questionnaire to all the patients who had undergone surgical ATR repair, evaluating their past medical history, sport- and work-related activities, drug use, and post-operative rehabilitation outcomes. **Results:** “Return to work activities/sport” was negatively predicted by the presence of a metabolic disorder ($\beta = -0.451$; OR = 0.637) and ‘open’ surgery technique ($\beta = -0.389$; OR = 0.678). “Medical complications” were significantly predicted by metabolic disorders ($\beta = 0.600$ (0.198); OR = 1.822) and was negatively related to ‘mini-invasive’ surgery (i.e., not ‘open’ nor ‘percutaneous’) ($\beta = -0.621$; OR = 0.537). “Immediate weightbearing” and “immediate walking without assistance” were negatively predicted by ‘open’ technique ($\beta = -0.691$; OR = 0.501 and $\beta = -0.359$ (0.174; OR = 0.698)). **Conclusions:** Metabolic conditions can strongly affect post-operative outcomes following surgical repair of acute Achilles tendon tears.

Keywords: Achilles tendon; rupture; dysmetabolism; diabetes mellitus; thyroid disease; hypercholesterolemia; obesity; surgery; rehabilitation

1. Introduction

The Achilles tendon is the strongest and largest tendon of the human body, and it is the most frequently ruptured, with an increased frequency in both recreational and competitive

sports [1]. In 85% of patients, the rupture occurs 2–7 cm proximal to its calcaneal insertion [2]. When diagnosed and treated within six weeks, Achilles tendon ruptures (ATRs) are classified as acute. These ruptures show an increasing incidence that varies from 11 to 37/100,000 in the European population, and they usually occur in active young and adult patients aged between 37 and 44 years [3]. ATRs usually occur more frequently in men than women, with male–female ratios from 1.7:1 to 30:1 [4–6]. ATRs can lead to persistent disability and functional impairment and can compromise patients' return to sport and everyday activities [7]. The current management of ATRs aims to restore function and avoid complications, either surgically or non-surgically [8,9]. Open, percutaneous, and mini-invasive techniques are all advocated as surgical options, even though conservative treatment has shown no significant differences compared to operative management [8,10,11]. The etiology of ATRs is multifactorial, and several intrinsic and extrinsic risk factors can be identified. While age, sex, and systemic conditions are non-modifiable predictors of rupture, BMI, use of different types of drugs, and sport involvement represent modifiable risk factors [12–14]. Metabolic diseases, such as diabetes mellitus, hypercholesterolemia, thyroid disorders, and obesity, impair tendon health, leading to Achilles tendinopathy and predisposing one to ATR [15]. Recently, the effects of metabolic disorders on tendons have been studied; these conditions modify the histology, mechanical structure, and healing capabilities of the tendons [16–18]. However, the association between these conditions and ATR has not yet been clarified.

The purposes of the present study were first to observe the incidence of metabolic diseases in patients with an ATR, and then to identify any significant differences in terms of patients' medical records, surgical approaches used, rehabilitation, and return to sport and/or everyday life activities.

2. Material and Methods

We retrospectively surveyed patients who had attended the Orthopedic Outpatient Clinics and the Accident and Emergency Departments of five different hospitals in Italy for ATRs: Ospedali Riuniti San Giovanni di Dio e Ruggi d'Aragona, Salerno, Tor Vergata University Hospital, Rome, University Hospital of Padova, San Camillo-Forlanini Hospital, Rome, and Sant'Anna Hospital, Como. Complete medical histories were collected. Then, through telephone interviews, we administered a questionnaire to all of the patients who had been surgically treated for ATRs (Table 1). The inclusion criteria were that (1) patients had suffered an ATR and (2) had undergone surgery between January 2003 and December 2021. Patients who suffered from a head trauma or coma and patients who did not consent to data treatment were excluded. Personal data of the patients were recorded (sex, age, and BMI). Then, comorbidities of the patients were investigated, especially the patients' medical history of type I (T1DM) or II diabetes mellitus (T2DM), obesity, thyroid disease (hypothyroidism and hyperthyroidism), and hypercholesterolemia. The diagnosis of Achilles tendon rupture was performed by a fully trained orthopedic surgeon using clinical tests (palpation, calf squeeze test, knee flexion test). The present study was approved and registered by the ethics committee of the University of Salerno (project ID 0096390, 19 June 2020) and was performed according to the principles expressed in the Declaration of Helsinki. Descriptive statistics are reported in Tables 2 and 3.

Table 1. Telephone questionnaire administered to the participants. Note: BMI = Body Mass Index; HRT = Hormone Replacement Therapy.

Name and Surname:

TELEPHONE QUESTIONNAIRE

Patients admitted to _____, who underwent an Achilles tendon reconstruction surgery during the period _____. The data collection took place in the period _____. The questionnaire consists of **26 questions**, of which **11** have dichotomous answers (YES/NO), **10** have multiple answers, and **5** have open answers.

Anthropometric data of the patient:

- weight: kg
- height: cm
- BMI:

QUESTIONS:

1. If a woman, **Menopause?** YES NO

2. If yes, take HRT? YES NO

3. What is your work activity?

4. Type of rupture of the Achilles tendon?

- unilateral
- bilateral
- total
- re-rupture

5. Do you have a family history of tendon rupture/tendinopathies?

- father
- mother
- sister
- brother
- uncle
- aunt
- cousin
- female cousin
- NO/is not aware

6. Are you taking any drugs? YES NO

7. If so, which drugs?

8. Before the Achilles tendon rupture, have you had targeted therapy with antibiotics (quinolones), steroids, or others? YES NO

9. If so, which drugs?

10. Do you suffer from any noteworthy pathologies? YES NO

Table 1. *Cont.*

Name and Surname:	
TELEPHONE QUESTIONNAIRE	
11. If so, which pathologies?	
- hypercholesterolemia	<input type="checkbox"/>
- diabetes mellitus	<input type="checkbox"/>
- hyperthyroidism	<input type="checkbox"/>
- hypothyroidism	<input type="checkbox"/>
- obesity	<input type="checkbox"/>
12. Have you ever suffered from tendon conditions?	YES <input type="checkbox"/> NO <input type="checkbox"/>
13. If so, which tendons?	
14. Have you ever suffered from localized problems at the Achilles tendon level?	YES <input type="checkbox"/> NO <input type="checkbox"/>
15. Which type of these:	
- tendon rupture (relapse)	<input type="checkbox"/>
- Achilles peritendinitis	<input type="checkbox"/>
- Achilles tendinosis	<input type="checkbox"/>
- Achilles insertional tendinopathy	<input type="checkbox"/>
- calcaneal apophysite (Sever’s disease)	<input type="checkbox"/>
- other	<input type="checkbox"/>
16. Do you practice sports?	YES <input type="checkbox"/> NO <input type="checkbox"/>
17. If so, what kind?	
- competitive	<input type="checkbox"/>
- not competitive	<input type="checkbox"/>
18. What kind of strain/overload does it exert on the muscle–tendon apparatus during work?	
- none	<input type="checkbox"/>
- light	<input type="checkbox"/>
- moderate	<input type="checkbox"/>
- intense	<input type="checkbox"/>
19. Did you engage in strenuous exercise or overload stress prior to the tendon rupture?	YES <input type="checkbox"/> NO <input type="checkbox"/>
20. The surgery was performed with the following technique:	
- open	<input type="checkbox"/>
- minimally invasive	<input type="checkbox"/>
- percutaneous	<input type="checkbox"/>
21. Were there any complications after surgery?	YES <input type="checkbox"/> NO <input type="checkbox"/>

Table 1. Cont.

Name and Surname:	
TELEPHONE QUESTIONNAIRE	
22. If so, what kind?	
- superficial infections	<input type="checkbox"/>
- deep tissue infections	<input type="checkbox"/>
- surgical wound repair defects	<input type="checkbox"/>
23. How long did it take to start loading?	
- immediately	<input type="checkbox"/>
- 6 weeks after surgery	<input type="checkbox"/>
- after 6 weeks	<input type="checkbox"/>
24. How long after were you able to walk independently without any help?	
- 1 month	<input type="checkbox"/>
- 2 months	<input type="checkbox"/>
- 3 months	<input type="checkbox"/>
25. How long did it take for you to start sports?	
- after 6 months	<input type="checkbox"/>
- 12 months	<input type="checkbox"/>
26. Do you think you have returned to the previous functional sport/work level?	YES <input type="checkbox"/> NO <input type="checkbox"/>

Table 2. Baseline demographic characteristics. Note: ATR = Achilles Tendon Rupture; BMI = Body Mass Index; SD = Standard Deviation.

	Patients with ATR (n)	Female (%)	Male (%)	BMI (Mean)	Mean Age (SD)
Total	340	59	281	26.15	45 (±13.06)
Dysmetabolic	95	27	68	26.87	51 (±14.19)
Non-Dysmetabolic	245	32	213	25.87	43 (±11.77)

Table 3. Baseline characteristics of the dysmetabolic group.

	Diabetes Mellitus	Thyroid Diseases	Obesity	Hypercholesterolemia
Patients (n)	16	17	22	40
Male (%)	9 (56%)	2 (12%)	18 (82%)	39 (98%)
Female (%)	7 (44%)	15 (88%)	4 (8%)	1 (2%)
Mean Age (years)	48	60	50	51

3. Statistical Analysis

Statistical analyses were performed with the R software (R-core project [19,20]) and the following packages: psych [21], lme4 [22], lavaan [23,24], semPlot, and ggplot2.

A multiple-multivariate binary logistic regression (*'probit'* link function) was used to investigate the association between literature-based predictors and four literature-relevant outcomes evaluated in patients with Achilles tendon tears. In more detail, the dependent binary variables (outcomes) were (A) 'Return to sport/work related activities' (no/yes), (B) 'Medical complications' (no/yes), (C) 'Immediate weightbearing' (no/yes), and (D) 'Immediate walking without assistance' (no/yes). On the contrary, independent variables

(predictors) were: (A) ‘Familiar history’ (no/yes), (B) ‘Past agonistic sport’ (no/yes), (C) ‘Dysmetabolism’ (no/yes), (D) ‘BMI’, € ‘Surgery: ‘open’ (no/yes), (F) ‘Surgery: ‘percutaneous’ (no/yes), and (G) ‘Age of surgery’ (≤ 50 y.o./ >50 y.o.). The p -value was set to 0.05. All reported beta coefficients and odds ratios are unstandardized.

4. Results

The medical records of 500 patients surgically treated for Achilles tendon rupture were collected from five different hospitals in Italy from 2003 to 2021. Of those, 160 patients did not consent to the post-operative interviews, and therefore were not part of the present study. The remaining 340 patients were allocated to one of two groups based on a medical history of metabolic diseases: 95 patients (28%) had a medical record of diabetes mellitus, obesity, hypercholesterolemia, and/or thyroid conditions, and they were allocated to the dysmetabolic group; 245 patients (72%) who had no history of metabolic diseases were allocated to the non-dysmetabolic group. The baseline demographic characteristics of the population are reported in Table 2. Further details about the frequency and baseline characteristics of the dysmetabolic patients are shown in Table 3.

The first outcome of the multiple-multivariate logistic regression, “Return to work activities/sport”, was negatively predicted by dysmetabolism ($\beta = -0.451$ (0.164), 95% CI $_{\beta}$: from -0.771 to -0.130 ; OR = 0.637, 95% CI $_{OR}$: from 0.462 to 0.878) and ‘open’ surgery technique ($\beta = -0.389$ (0.179), 95% CI $_{\beta}$: from -0.740 to -0.038 ; OR = 0.678, 95% CI $_{OR}$: from 0.477 to 0.962), while it was positively predicted by age at which the surgery was performed ($\beta = 0.629$ (0.167), 95% CI $_{\beta}$: from 0.300 to 0.957; OR = 1.875, 95% CI $_{OR}$: from 1.350 to 2.603). The explained variance (R^2) was equal to 0.131. The second outcome of the multiple-multivariate logistic regression, “Medical complications”, was significantly predicted by dysmetabolism ($\beta = 0.600$ (0.198), 95% CI $_{\beta}$: from 0.211 to 0.989; OR = 1.822, 95% CI $_{OR}$: from 1.235 to 2.688), while it was negatively related to ‘mini-invasive’ surgery (i.e., not ‘open’ nor ‘percutaneous’) ($\beta = -0.621$ (0.253), 95% CI $_{\beta}$: from -1.117 to -0.125 ; OR = 0.537, 95% CI $_{OR}$: from 0.327 to 0.883). The explained variance (R^2) was 0.097. The third outcome of the multiple-multivariate logistic regression, “Immediate weightbearing”, was significantly predicted by past competitive sport experiences ($\beta = 0.396$ (0.169), 95% CI $_{\beta}$: from 0.063 to 0.728; OR = 1.485, 95% CI $_{OR}$: from 1.066 to 2.070) and age at which the surgery was performed ($\beta = 0.342$ (0.171), 95% CI $_{\beta}$: from 0.007 to 0.676; OR = 1.407, 95% CI $_{OR}$: from 1.007 to 1.967), while it was negatively predicted by ‘open’ technique ($\beta = -0.691$ (0.205), 95% CI $_{\beta}$: from -1.093 to -0.288 ; OR = 0.501, 95% CI $_{OR}$: from 0.335 to 0.749). The explained variance (R^2) was equal to 0.125. Lastly, the first outcome of the multiple-multivariate logistic regression, “Immediate walking without assistance”, was significantly predicted by past competitive sport experiences ($\beta = 0.406$ (0.148), 95% CI $_{\beta}$: from 0.115 to 0.697; OR = 1.501, 95% CI $_{OR}$: from 1.122 to 2.007) but negatively predicted by ‘open’ surgery technique ($\beta = -0.359$ (0.174), 95% CI $_{\beta}$: from -0.700 to -0.019 ; OR = 0.698, 95% CI $_{OR}$: from 0.497 to 0.981). The explained variance (R^2) was 0.065. All results are reported in detail in Tables 4 and 5.

Table 4. Multiple multivariate logistic regression. Note: OUTC. = outcome variable; PRED. = predictor variable; β^* = standardized beta coefficient; β = unstandardized beta coefficient; s.e. = standard error; 95% CI [L-U] = lower and upper 95% confidence interval; BMI = Body Mass Index.

	Variable		β^*	β (s.e.)	95% CI [L-U]	z-Value	p-Value	OR	95% CI [L-U]
OUTC.	Return to work/sport activities								
PRED.	Familiarity	a1	-0.021	-0.068 (0.209)	[-0.477; 0.341]	-0.327	0.744	0.934	[0.621; 1.406]
PRED.	Past agonistic sport	b1	0.123	0.268 (0.151)	[-0.027; 0.563]	1.779	0.075	1.307	[0.973; 1.756]
PRED.	Dysmetabolism	c1	-0.189	-0.451 (0.164)	[-0.771; -0.130]	-2.758	0.006	0.637	[0.462; 0.878]
PRED.	BMI	d1	0.046	0.016 (0.024)	[-0.032; 0.064]	0.648	0.517	1.016	[0.968; 1.066]
PRED.	Surgery ‘open’	e1	-0.178	-0.389 (0.179)	[-0.740; -0.038]	-2.174	0.030	0.678	[0.477; 0.962]
PRED.	Surgery ‘percutaneous’	f1	-0.069	-0.156 (0.188)	[-0.525; 0.213]	-0.830	0.407	0.855	[0.591; 1.237]
PRED.	Surgery ‘mini-invasive’	g1	0.053	0.131 (0.207)	[-0.275; 0.537]	0.630	0.529	1.139	[0.759; 1.710]
PRED.	Age of surgery	h1	0.274	0.629 (0.167)	[0.300; 0.957]	3.754	<0.001	1.875	[1.350; 2.603]

Table 4. Cont.

Variable		β^*	β (s.e.)	95% CI [L-U]	z-Value	p-Value	OR	95% CI [L-U]	
OUTC.	Medical complications								
PRED.	Familiar history	a2	0.109	0.355 (0.256)	[−0.146; 0.857]	1.389	0.165	1.426	[0.864; 2.355]
PRED.	Past agonistic sport	b2	0.080	0.171 (0.188)	[−0.197; 0.539]	0.911	0.362	1.187	[0.821; 1.714]
PRED.	Dysmetabolism	c2	0.256	0.600 (0.198)	[0.211; 0.989]	3.023	0.002	1.822	[1.235; 2.688]
PRED.	BMI	d2	−0.008	−0.003 (0.027)	[−0.056; 0.050]	−0.101	0.919	0.997	[0.946; 1.052]
PRED.	Surgery ‘open’	e2	−0.122	−0.261 (0.205)	[−0.663; 0.141]	−1.271	0.204	0.770	[0.515; 1.152]
PRED.	Surgery ‘percutaneous’	f2	−0.142	−0.313 (0.241)	[−0.785; 0.159]	−1.300	0.193	0.731	[0.456; 1.172]
PRED.	Surgery ‘mini-invasive’	g2	−0.255	−0.621 (0.253)	[−1.117; −0.125]	−2.452	0.014	0.537	[0.327; 0.883]
PRED.	Age of surgery	h2	−0.046	−0.105 (0.197)	[−0.491; 0.282]	−0.530	0.596	0.901	[0.612; 1.326]
OUTC.	Immediate weightbearing								
PRED.	Familiar history	a3	0.107	0.356 (0.229)	[−0.093; 0.806]	1.554	0.120	1.428	[0.911; 2.238]
PRED.	Past agonistic sport	b3	0.182	0.396 (0.169)	[0.063; 0.728]	2.335	0.020	1.485	[1.066; 2.070]
PRED.	Dysmetabolism	c3	−0.085	−0.203 (0.184)	[−0.565; 0.158]	−1.103	0.270	0.816	[0.568; 1.171]
PRED.	BMI	d3	0.054	0.019 (0.025)	[−0.029; 0.067]	0.760	0.447	1.019	[0.971; 1.069]
PRED.	Surgery ‘open’	e3	−0.318	−0.691 (0.205)	[−1.093; −0.288]	−3.365	0.001	0.501	[0.335; 0.749]
PRED.	Surgery ‘percutaneous’	f3	−0.053	−0.119 (0.202)	[−0.516; 0.277]	−0.590	0.555	0.887	[0.597; 1.319]
PRED.	Surgery ‘mini-invasive’	g3	−0.102	−0.252 (0.193)	[−0.631; 0.126]	−1.307	0.191	0.777	[0.532; 1.134]
PRED.	Age of surgery	h3	0.149	0.342 (0.171)	[0.007; 0.676]	1.999	0.046	1.407	[1.007; 1.967]
OUTC.	Immediate walking without assistance								
PRED.	Familiarity	a4	−0.035	−0.111 (0.219)	[−0.541; 0.318]	−0.508	0.611	0.894	[0.582; 1.375]
PRED.	Past agonistic sport	b4	0.193	0.406 (0.148)	[0.115; 0.697]	2.734	0.006	1.501	[1.122; 2.007]
PRED.	Dysmetabolism	c4	−0.080	−0.185 (0.161)	[−0.500; 0.130]	−1.150	0.250	0.831	[0.606; 1.139]
PRED.	BMI	d4	0.033	0.011 (0.023)	[−0.034; 0.056]	0.474	0.636	1.011	[0.966; 1.058]
PRED.	Surgery ‘open’	e4	−0.171	−0.359 (0.174)	[−0.700; −0.019]	−2.070	0.038	0.698	[0.497; 0.981]
PRED.	Surgery ‘percutaneous’	f4	−0.130	−0.282 (0.182)	[−0.638; 0.075]	−1.548	0.122	0.755	[0.528; 1.078]
PRED.	Surgery ‘mini-invasive’	g4	−0.002	−0.004 (0.201)	[−0.399; 0.391]	−0.019	0.985	0.996	[0.671; 1.478]
PRED.	Age of surgery	h4	0.087	0.192 (0.162)	[−0.125; 0.509]	1.187	0.235	1.211	[0.883; 1.663]

Table 5. Covariances (standardized) between dichotomous outcomes of the multiple-multivariate regression analysis. Note: ** $p = 0.001$; *** $p < 0.001$.

	Return to Work/Sport Activities	Medical Complications	Immediate Weightbearing	Immediate Walking without Assistance
Return to work/sport activities	-			
Medical complications	−0.076	-		
Immediate weightbearing	0.065	−0.101	-	
Immediate walking without assistance	0.279 **	−0.346 ***	0.561 ***	-

5. Discussion

This study showed that some metabolic conditions can strongly affect the post-operative outcome of patients who have undergone surgery to repair an acute Achilles tendon tear. Ninety-five patients (28%) had a medical history of metabolic pathologies. Of them, hypercholesterolemia (40 patients, 42%) and obesity (22 patients, 23%) were the most frequently reported, followed by thyroid disorders, such as hypothyroidism, hyperthyroidism, and Hashimoto disease (17 patients, 18%), as well as diabetes mellitus (16 patients, 17%). The multivariate statistical analysis showed that the diagnosis of a dysmetabolic disease significantly predicted the risk of post-operative complications and a delayed return to sport and work activities (Tables 4 and 5).

Hypercholesterolemia was the most common metabolic condition in our study population of patients with ATRs. Serum cholesterol is carried in various form, of which LDL cholesterol (LDL-C) is the most atherogenic [25]. Indeed, patients with high levels of total cholesterol (>200 mg/dL; 5.17 mmol) and LDL cholesterol (>100 mg/dL; 2.58 mmol) can be diagnosed with hypercholesterolemia [26]. In addition, 1/500 people per year can present with familial hypercholesterolemia (HeFH), which arises from the heterozygous mutation

of the gene that codifies for the LDL receptor [27]. The lack of this receptor, which usually removes LDL from the serum, leads to higher levels of blood LDL cholesterol [28]. High levels of serum lipids can negatively affect tendon homeostasis [29,30]. The Achilles tendon structure is characterized by the presence of type I collagen, which accounts for 95% of the tendon dry weight [31]. High levels of LDL-C increase the metalloproteinase (MMP) activity, eliciting a chronic inflammatory response and impacting the tendon structure [30]. In a recent retrospective study, lipid blood levels were compared among patients who suffered an ATR and healthy controls. Yang et al. [18] found that serum cholesterol, triglyceride, and LDL levels in patients who ruptured their Achilles tendon were significantly higher than those in healthy controls [18]. The low-grade chronic inflammation found in patients with high serum cholesterol levels is commonly reported in obese subjects as well. Obesity is a modifiable risk factor for several musculoskeletal conditions [32]. The World Health Organization recognized BMI values over 30 kg/m² as a cutoff value for adult obesity, while other measurements, such as the waist and hip ratio, have been used to define the pattern of fat distribution [33]. Adipose tissue releases hormones and proteins that influence tenocyte function and homeostasis [34]. Adipokines play a crucial part in this molecular pathway, causing an increase in MMP activity and the migration of macrophages and mast cells to the adipose tissue, leading to a reduction in their homeostatic functions [35,36]. As a result, a chronic inflammatory state, and alterations in the type I/type III collagen synthesis result in the tendon being less resistant to stress and more at risk of rupture [37]. The role of mechanical loads on weightbearing tendons in obese patients is still debated. Indeed, obesity is associated with a high risk of tendon tears, even in the upper extremities, such as rotator cuff tears [38,39]. A recent systematic review compared the relationship of being overweight and suffering from tendon tears: Sedentary lifestyle was identified as a risk factor for rupture, while mechanical loads are responsible for pain and tendon inflammation [40]. Increased abdominal adiposity, chronic inflammation status, and endocrine system dysfunction are also three of the main features of diabetes mellitus [41]. Type 2 diabetes mellitus (T2DM) is a public health challenge because of its clinical and economical burdens on the worldwide population [42]. In the US alone, nearly 10% of the population has been diagnosed with T2DM, while 83 million people have been classified as pre-diabetic with a high risk of disease progression in 5 years [43,44]. The effects of diabetes mellitus on tendons have been investigated in animal and human models, finding that the crosslink reaction between collagens and advanced glycosylation end-products (AGEs)—highly induced by a persistent state of hyperglycemia—is accountable for the disruption of tendon homeostasis [45–47]. Zakaria et al. investigated the incidence and predictors of tendon rupture requiring hospitalization in patients affected by T2DM versus healthy controls, identifying a significantly higher risk of tendon rupture in diabetic subjects [48]. In addition, the structural setting of tendons can be significantly altered by thyroid hormones [49], as shown by in vitro and in vivo studies in animal and human tendons [50–56]. Oliva et al. [57] investigated the healing capabilities of the combination of T3 and ascorbic acid (AA) compared to the administration of bone marrow mesenchymal stem cells alone in a rat model of Achilles tendon injury. The association of T3 and AA can improve Achilles tendon healing in terms of the type I/type III collagen ratio, tendon stiffness, and strength [57]. The current evidence shows that metabolic diseases, such as T2DM and thyroid diseases, are not only risk factors for tendon ruptures, but also predictive of delayed post-operative healing [52,58,59]. In the current study, we investigated how long it took for dysmetabolic and healthy patients to return to sport and work activities; the presence of any metabolic condition led to a delayed return to both sport and work activities. Dombrowski et al. [60] investigated the role of comorbidities in the development of post-operative complications, showing a significant relationship between obesity or T2DM and surgical site infections [61]. In accordance, our study showed that metabolic conditions can be regarded as positive predictive factors for post-operative complications, such as deep and superficial surgical site infection and delayed wound healing. Even though there is no consensus about the gold-standard strategy for treating acute ATRs, it

appears that the choice of the surgical technique can play a role in the assessment of risk for post-operative complications. Recently, a randomized superiority trial in 39 UK hospitals compared surgical and conservative treatments after an ATR. The main outcomes of interest were the Achilles tendon rupture score (ATRS) and the re-rupture rate in both groups; patients treated non-surgically experienced the same results as those in the surgically treated group [10]. Consistently with the results reported by Del Buono et al. [62], we found that choosing a 'mini-invasive' over an 'open' surgical approach is associated with a significant reduction in post-operative complications. The surgical technique used can influence the rehabilitation protocol in terms of immediate weightbearing and walking without assistance. Indeed, open techniques were associated ($p < 0.001$) with a statistically significant longer time of weightbearing (>40 days) and walking (>3 months) in both dysmetabolic and healthy patients. We also investigated the relationship between patients' participation in competitive sports and the surgical treatment of ATRs, finding no statistically significant differences between athletes and non-athletes. Even though the relationship between ATRs and systemic conditions has been investigated [63,64], the current investigation is the first study in the Italian population to investigate the influence of T2DM, thyroid diseases, hypercholesterolemia, and obesity on acute Achilles tendon ruptures. Obviously, this study has some limitations. First, the small number of patients with metabolic conditions could be related to the relatively young age range at which an ATR occurs. Indeed, patients with a family history of metabolic diseases could develop the condition later than the tendon rupture. The surgeons who took part in the study did not use the same surgical techniques and did not follow the same rehabilitation protocols, which could lead to a higher risk of bias. However, this reflects the standard practice in each of the centers involved in the present study and allows greater generalization of the results. Retrospective assessment of demographic data was carried out through telephone interviews, leading to an inevitable lack of relevant medical information. Furthermore, the questionnaire used to investigate the medical histories of the patients has not yet been validated. This limitation could increase the risk of bias in the study, and it could represent the aim of further studies to achieve more scientifically valid findings.

6. Conclusions

Metabolic conditions can strongly affect the post-operative outcomes of surgical reconstruction of the Achilles tendon.

Author Contributions: Conceptualization, F.O. and E.M.; methodology, G.A., A.G.V., C.B. and C.F.; investigation, E.M., C.B., M.S., P.R. and G.A.; data curation, E.M., G.A., J.P., A.A.R. and S.M.; writing—original draft preparation, F.O., N.M. and E.M.; writing, interpretation of results, devising the questionnaire, and review and editing, N.M. and F.O.; visualization, E.M., G.O. and G.A.; supervision, N.M. and F.O. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of the University of Salerno (project ID 0096390, 19 June 2022).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ganestam, A.; Kalleose, T.; Troelsen, A.; Barfod, K.W. Increasing incidence of acute Achilles tendon rupture and a noticeable decline in surgical treatment from 1994 to 2013. A nationwide registry study of 33,160 patients. *Knee Surg. Sports Traumatol. Arthrosc.* **2016**, *24*, 3730–3737. [[CrossRef](#)] [[PubMed](#)]
2. Maffulli, N.; Via, A.G.; Oliva, F. Chronic Achilles Tendon Disorders: Tendinopathy and Chronic Rupture. *Clin. Sports Med.* **2015**, *34*, 607–624. [[CrossRef](#)] [[PubMed](#)]

3. Huttunen, T.T.; Kannus, P.; Rolf, C.; Fellander-Tsai, L.; Mattila, V.M. Acute achilles tendon ruptures: Incidence of injury and surgery in Sweden between 2001 and 2012. *Am. J. Sports Med.* **2014**, *42*, 2419–2423. [[CrossRef](#)] [[PubMed](#)]
4. Suchak, A.A.; Bostick, G.; Reid, D.; Blitz, S.; Jomha, N. The incidence of Achilles tendon ruptures in Edmonton, Canada. *Foot Ankle Int.* **2005**, *26*, 932–936. [[CrossRef](#)]
5. Scott, A.; Grewal, N.; Guy, P. The seasonal variation of Achilles tendon ruptures in Vancouver, Canada: A retrospective study. *BMJ Open* **2014**, *4*, e004320. [[CrossRef](#)]
6. Sheth, U.; Wasserstein, D.; Jenkinson, R.; Moineddin, R.; Kreder, H.; Jaglal, S.B. The epidemiology and trends in management of acute Achilles tendon ruptures in Ontario, Canada: A population-based study of 27,607 patients. *Bone Jt. J.* **2017**, *99-B*, 78–86. [[CrossRef](#)]
7. Chianca, V.; Zappia, M.; Oliva, F.; Luca, B.; Maffulli, N. Post-operative MRI and US appearance of the Achilles tendons. *J. Ultrasound* **2020**, *23*, 387–395. [[CrossRef](#)]
8. Maffulli, N.; Peretti, G.M. Surgery or conservative management for Achilles tendon rupture? *BMJ* **2019**, *364*, k5344. [[CrossRef](#)]
9. Maffulli, N.; Oliva, F.; Migliorini, F. Check-rein technique for Achilles tendon elongation following conservative management for acute Achilles tendon ruptures: A two-year prospective clinical study. *J. Orthop. Surg. Res.* **2021**, *16*, 690. [[CrossRef](#)]
10. Costa, M.L.; Achten, J.; Marian, I.R.; Dutton, S.J.; Lamb, S.E.; Ollivere, B.; Maredza, M.; Petrou, S.; Kearney, R.S.; UKSTAR Trial Collaborators. Plaster cast versus functional brace for non-surgical treatment of Achilles tendon rupture (UKSTAR): A multicentre randomised controlled trial and economic evaluation. *Lancet* **2020**, *395*, 441–448. [[CrossRef](#)]
11. Ochen, Y.; Beks, R.B.; van Heijl, M.; Hietbrink, F.; Leenen, L.P.H.; van der Velde, D.; Heng, M.; van der Meijden, O.; Groenwold, R.H.H.; Houwert, R.M. Operative treatment versus nonoperative treatment of Achilles tendon ruptures: Systematic review and meta-analysis. *BMJ* **2019**, *364*, k5120. [[CrossRef](#)]
12. Claessen, F.M.; de Vos, R.J.; Reijman, M.; Meuffels, D.E. Predictors of primary Achilles tendon ruptures. *Sports Med.* **2014**, *44*, 1241–1259. [[CrossRef](#)] [[PubMed](#)]
13. Kannus, P.; Natri, A. Etiology and pathophysiology of tendon ruptures in sports. *Scand J. Med. Sci. Sports* **1997**, *7*, 107–112. [[CrossRef](#)] [[PubMed](#)]
14. Oliva, F.; Marsilio, E.; Asparago, G.; Frizziero, A.; Berardi, A.C.; Maffulli, N. The Impact of Hyaluronic Acid on Tendon Physiology and Its Clinical Application in Tendinopathies. *Cells* **2021**, *10*, 3081. [[CrossRef](#)] [[PubMed](#)]
15. Gaii Via, A.; Oliva, F.; Padulo, J.; Oliva, G.; Maffulli, N. Insertional Calcific Tendinopathy of the Achilles Tendon and Dysmetabolic Diseases: An Epidemiological Survey. *Clin. J. Sport Med.* **2020**, *32*, e68–e73. [[CrossRef](#)]
16. Oliva, F.; Piccirilli, E.; Berardi, A.C.; Frizziero, A.; Tarantino, U.; Maffulli, N. Hormones and tendinopathies: The current evidence. *Br. Med. Bull.* **2016**, *117*, 39–58. [[CrossRef](#)]
17. Nichols, A.E.C.; Oh, I.; Loiselle, A.E. Effects of Type II Diabetes Mellitus on Tendon Homeostasis and Healing. *J. Orthop. Res.* **2020**, *38*, 13–22. [[CrossRef](#)]
18. Yang, Y.P.; Tao, L.Y.; Gao, J.N.; Wang, P.; Jiang, Y.F.; Zheng, L.M.; Zhao, Y.M.; Ao, Y.F. Elevated lipid levels in patients with achilles tendon ruptures: A retrospective matching study. *Ann. Transl. Med.* **2020**, *8*, 217. [[CrossRef](#)]
19. R Core Team. *R: A Language and Environment for Statistical Computing*; R Foundation for Statistical Computing: Vienna, Austria, 2017.
20. R Core Team. *The R Project for Statistical Computing*; R Foundation for Statistical Computing: Vienna, Austria, 2014.
21. Revelle, W. *Psych: Procedures for Personality and Psychological Research*; Northwestern University: Evanston, IL, USA, 2018.
22. Bates, D.; Maechler, M.; Bolker, B.; Walker, S. Fitting Linear Mixed-Effects Models Using lme4. *J. Stat. Softw.* **2015**, *67*, 1–48. [[CrossRef](#)]
23. Rosseel, Y. Lavaan: An R Package for Structural Equation Modeling. *J. Stat. Softw.* **2012**, *48*, 1–36. [[CrossRef](#)]
24. Rosseel, Y.; Oberski, D.; Byrnes, J.; Vanbrabant, L.; Savalei, V.; Merkle, E.; Hallquist, M.; Rhemtulla, M.; Katsikatsou, M.; Barendse, M. Package ‘Lavaan’. 2015. Available online: <http://cran.r-project.org/web/packages/lavaan/lavaan.pdf> (accessed on 16 March 2022).
25. Coombes, B.; Tucker, K.; Hug, F.; Scott, A.; Geytenbeek, M.; Cox, E.; Gajanand, T.; Coombes, J. Relationships between cardiovascular disease risk factors and Achilles tendon structural and mechanical properties in people with Type 2 Diabetes. *Muscles Ligaments Tendons J.* **2019**, *9*, 395. [[CrossRef](#)]
26. Grundy, S.M.; Stone, N.J.; Bailey, A.L.; Beam, C.; Birtcher, K.K.; Blumenthal, R.S.; Braun, L.T.; de Ferranti, S.; Faiella-Tommasino, J.; Forman, D.E.; et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J. Am. Coll. Cardiol.* **2019**, *73*, e285–e350. [[CrossRef](#)] [[PubMed](#)]
27. Reiner, Z. Management of patients with familial hypercholesterolaemia. *Nat. Rev. Cardiol.* **2015**, *12*, 565–575. [[CrossRef](#)]
28. Abate, M.; Salini, V.; Andia, I. Tendons Involvement in Congenital Metabolic Disorders. *Adv. Exp. Med. Biol.* **2016**, *920*, 117–122. [[CrossRef](#)]
29. Biancalana, A.; Velloso, L.A.; Taboga, S.R.; Gomes, L. Implications of obesity for tendon structure, ultrastructure and biochemistry: A study on Zucker rats. *Micron* **2012**, *43*, 463–469. [[CrossRef](#)] [[PubMed](#)]
30. Rekhter, M.D.; Hicks, G.W.; Brammer, D.W.; Hallak, H.; Kindt, E.; Chen, J.; Rosebury, W.S.; Anderson, M.K.; Kuipers, P.J.; Ryan, M.J. Hypercholesterolemia causes mechanical weakening of rabbit atheroma: Local collagen loss as a prerequisite of plaque rupture. *Circ. Res.* **2000**, *86*, 101–108. [[CrossRef](#)]

31. Liu, S.H.; Yang, R.S.; al-Shaikh, R.; Lane, J.M. Collagen in tendon, ligament, and bone healing. A current review. *Clin. Orthop. Relat. Res.* **1995**, *318*, 265–278.
32. Wearing, S.C.; Hennig, E.M.; Byrne, N.M.; Steele, J.R.; Hills, A.P. Musculoskeletal disorders associated with obesity: A biomechanical perspective. *Obes. Rev.* **2006**, *7*, 239–250. [[CrossRef](#)]
33. Flegal, K.M.; Carroll, M.D.; Ogden, C.L.; Johnson, C.L. Prevalence and trends in obesity among US adults, 1999–2000. *JAMA* **2002**, *288*, 1723–1727. [[CrossRef](#)]
34. Del Buono, A.; Battery, L.; Denaro, V.; Maccauro, G.; Maffulli, N. Tendinopathy and inflammation: Some truths. *Int. J. Immunopathol. Pharmacol.* **2011**, *24*, 45–50. [[CrossRef](#)]
35. Battery, L.; Maffulli, N. Inflammation in overuse tendon injuries. *Sports Med. Arthrosc. Rev.* **2011**, *19*, 213–217. [[CrossRef](#)]
36. Lago, R.; Gomez, R.; Otero, M.; Lago, F.; Gallego, R.; Dieguez, C.; Gomez-Reino, J.J.; Gualillo, O. A new player in cartilage homeostasis: Adiponectin induces nitric oxide synthase type II and pro-inflammatory cytokines in chondrocytes. *Osteoarthr. Cartil.* **2008**, *16*, 1101–1109. [[CrossRef](#)] [[PubMed](#)]
37. Jozsa, L.; Balint, B.J.; Reffy, A.; Demel, Z. Fine structural alterations of collagen fibers in degenerative tendinopathy. *Arch. Orthop. Trauma. Surg.* **1984**, *103*, 47–51. [[CrossRef](#)] [[PubMed](#)]
38. Franceschi, F.; Papalia, R.; Paciotti, M.; Franceschetti, E.; Di Martino, A.; Maffulli, N.; Denaro, V. Obesity as a risk factor for tendinopathy: A systematic review. *Int. J. Endocrinol.* **2014**, *2014*, 670262. [[CrossRef](#)] [[PubMed](#)]
39. Wendelboe, A.M.; Hegmann, K.T.; Gren, L.H.; Alder, S.C.; White, G.L., Jr.; Lyon, J.L. Associations between body-mass index and surgery for rotator cuff tendinitis. *J. Bone Jt. Surg. Am.* **2004**, *86*, 743–747. [[CrossRef](#)]
40. Macchi, M.; Spezia, M.; Elli, S.; Schiaffini, G.; Chisari, E. Obesity Increases the Risk of Tendinopathy, Tendon Tear and Rupture, and Postoperative Complications: A Systematic Review of Clinical Studies. *Clin. Orthop. Relat. Res.* **2020**, *478*, 1839–1847. [[CrossRef](#)]
41. Dale, C.E.; Fatemifar, G.; Palmer, T.M.; White, J.; Prieto-Merino, D.; Zabaneh, D.; Engmann, J.E.L.; Shah, T.; Wong, A.; Warren, H.R.; et al. Causal Associations of Adiposity and Body Fat Distribution with Coronary Heart Disease, Stroke Subtypes, and Type 2 Diabetes Mellitus: A Mendelian Randomization Analysis. *Circulation* **2017**, *135*, 2373–2388. [[CrossRef](#)]
42. American Diabetes, A. Economic Costs of Diabetes in the U.S. in 2017. *Diabetes Care* **2018**, *41*, 917–928. [[CrossRef](#)]
43. Lin, J.; Thompson, T.J.; Cheng, Y.J.; Zhuo, X.; Zhang, P.; Gregg, E.; Rolka, D.B. Projection of the future diabetes burden in the United States through 2060. *Popul. Health Metr.* **2018**, *16*, 9. [[CrossRef](#)]
44. Boyle, J.P.; Thompson, T.J.; Gregg, E.W.; Barker, L.E.; Williamson, D.F. Projection of the year 2050 burden of diabetes in the US adult population: Dynamic modeling of incidence, mortality, and prediabetes prevalence. *Popul. Health Metr.* **2010**, *8*, 29. [[CrossRef](#)]
45. Li, Y.; Fessel, G.; Georgiadis, M.; Snedeker, J.G. Advanced glycation end-products diminish tendon collagen fiber sliding. *Matrix Biol.* **2013**, *32*, 169–177. [[CrossRef](#)]
46. Snedeker, J.G.; Gautieri, A. The role of collagen crosslinks in ageing and diabetes—The good, the bad, and the ugly. *Muscles Ligaments Tendons J.* **2014**, *4*, 303–308. [[CrossRef](#)]
47. Brito, A.; Martins, W.; Queiroz, P.; Santos, S.; Santos, T.; Souza, R.; Pereira, D.; Camila, A.; Thuany, M.; Esteves, A.; et al. Combined Treadmill Running and Insulin Therapy Favors the Stabilization of Glycemic Metabolic Parameters and Avoids Increased Achilles Tendon Rigidity in Diabetic Rats. *Muscles Ligaments Tendons J.* **2020**, *3*, 451–459. [[CrossRef](#)]
48. Zakaria, M.H.; Davis, W.A.; Davis, T.M. Incidence and predictors of hospitalization for tendon rupture in type 2 diabetes: The Fremantle diabetes study. *Diabet Med.* **2014**, *31*, 425–430. [[CrossRef](#)] [[PubMed](#)]
49. Oliva, F.; Piccirilli, E.; Berardi, A.C.; Tarantino, U.; Maffulli, N. Influence of Thyroid Hormones on Tendon Homeostasis. *Adv. Exp. Med. Biol.* **2016**, *920*, 133–138. [[CrossRef](#)] [[PubMed](#)]
50. Han, X.; Guo, L.; Wang, F.; Zhu, Q.; Yang, L. Contribution of PTHrP to mechanical strain-induced fibrochondrogenic differentiation in entheses of Achilles tendon of miniature pigs. *J. Biomech.* **2014**, *47*, 2406–2414. [[CrossRef](#)]
51. Ayala, J.; Rodriguez, M.; Jimenez, J.M.; Mendez, A.; Blanco, A. Occurrence and evolution of T3 fibroblast nuclei in healing tendons from growing chicks. *Scand J. Plast. Reconstr. Surg. Hand Surg.* **1991**, *25*, 217–220. [[CrossRef](#)]
52. Oliva, F.; Berardi, A.C.; Misiti, S.; Verga Falzacappa, C.; Iacone, A.; Maffulli, N. Thyroid hormones enhance growth and counteract apoptosis in human tenocytes isolated from rotator cuff tendons. *Cell Death Dis.* **2013**, *4*, e705. [[CrossRef](#)]
53. Berardi, A.C.; Oliva, F.; Berardocco, M.; la Rovere, M.; Accorsi, P.; Maffulli, N. Thyroid hormones increase collagen I and cartilage oligomeric matrix protein (COMP) expression in vitro human tenocytes. *Muscles Ligaments Tendons J.* **2014**, *4*, 285–291. [[CrossRef](#)]
54. Dorwart, B.B.; Schumacher, H.R. Joint effusions, chondrocalcinosis and other rheumatic manifestations in hypothyroidism. A clinicopathologic study. *Am. J. Med.* **1975**, *59*, 780–790. [[CrossRef](#)]
55. Oliva, F.; Osti, L.; Padulo, J.; Maffulli, N. Epidemiology of the rotator cuff tears: A new incidence related to thyroid disease. *Muscles Ligaments Tendons J.* **2014**, *4*, 309–314. [[CrossRef](#)] [[PubMed](#)]
56. Harvie, P.; Pollard, T.C.; Carr, A.J. Calcific tendinitis: Natural history and association with endocrine disorders. *J. Shoulder Elbow Surg.* **2007**, *16*, 169–173. [[CrossRef](#)] [[PubMed](#)]
57. Oliva, F.; Maffulli, N.; Gissi, C.; Veronesi, F.; Calciano, L.; Fini, M.; Brogini, S.; Gallorini, M.; Antonetti Lamorgese Passeri, C.; Bernardini, R.; et al. Combined ascorbic acid and T3 produce better healing compared to bone marrow mesenchymal stem cells in an Achilles tendon injury rat model: A proof of concept study. *J. Orthop. Surg. Res.* **2019**, *14*, 54. [[CrossRef](#)] [[PubMed](#)]

58. Abtahi, A.M.; Granger, E.K.; Tashjian, R.Z. Factors affecting healing after arthroscopic rotator cuff repair. *World J. Orthop.* **2015**, *6*, 211–220. [[CrossRef](#)]
59. Maffulli, N.; D'Addona, A.; Maffulli, G.D.; Gougoulis, N.; Oliva, F. Delayed (14–30 Days) Percutaneous Repair of Achilles Tendon Ruptures Offers Equally Good Results as Compared with Acute Repair. *Am. J. Sports Med.* **2020**, *48*, 1181–1188. [[CrossRef](#)]
60. Dombrowski, M.; Murawski, C.D.; Yasui, Y.; Chen, A.F.; Ewalefo, S.O.; Fourman, M.S.; Kennedy, J.G.; Hogan, M.V. Medical comorbidities increase the rate of surgical site infection in primary Achilles tendon repair. *Knee Surg. Sports Traumatol. Arthrosc.* **2019**, *27*, 2840–2851. [[CrossRef](#)]
61. Burrus, M.T.; Werner, B.C.; Park, J.S.; Perumal, V.; Cooper, M.T. Achilles Tendon Repair in Obese Patients Is Associated with Increased Complication Rates. *Foot Ankle Spec.* **2016**, *9*, 208–214. [[CrossRef](#)]
62. Del Buono, A.; Volpin, A.; Maffulli, N. Minimally invasive versus open surgery for acute Achilles tendon rupture: A systematic review. *Br. Med. Bull.* **2014**, *109*, 45–54. [[CrossRef](#)]
63. Cramer, A.; Jacobsen, N.C.; Hansen, M.S.; Sandholdt, H.; Holmich, P.; Barfod, K.W. Diabetes and treatment with orally administrated corticosteroids negatively affect treatment outcome at follow-up after acute Achilles tendon rupture. *Knee Surg Sports Traumatol. Arthrosc.* **2021**, *29*, 1584–1592. [[CrossRef](#)]
64. Oliva, F.; Bernardi, G.; De Luna, V.; Farsetti, P.; Gasparini, M.; Marsilio, E.; Piccirilli, E.; Tarantino, U.; Rugiero, C.; De Carli, A.; et al. I.S.Mu.L.T. Achilles tendon ruptures guidelines. *Muscles Ligaments Tendons J.* **2018**, *8*, 310–363. [[CrossRef](#)]